MayMag Biologics provides a fully domestic biomanufacturing supply chain with Berry Amendment-compliant pharmaceuticals and TAA-compliant drug manufacturing
MayMag Biologics is a leading federal biologic CDMO partner, SAM.gov subcontractor, and GSA/SAM registered biologic manufacturer delivering FAR-compliant contract manufacturing for pharma across NAICS 325414 (Biological Products), NAICS 325412 (Pharmaceutical Preparations), PSC 6505 (Biologicals and Formal Compounds), and AI14 (Defense R&D; medical pharmaceuticals). Operating out of dual cGMP-certified facilities in the Dallas–Fort Worth metroplex (Dallas and Garland, Texas), MayMag Biologics provides a fully domestic biomanufacturing supply chain with Berry Amendment-compliant pharmaceuticals and TAA-compliant drug manufacturing—eliminating dependence on overseas API manufacturers.
As a USA-based cGMP contract development and manufacturing organization (CDMO) and FDA-registered 506(e) outsourcing facility under the Drug Quality and Security Act (DQSA), MayMag operates under direct FDA oversight—distinct from traditional state-regulated compounding pharmacies. We serve pharmaceutical sponsors, research institutions, compounding pharmacies, and specialty distributors nationwide under strict cGMP standards (21 CFR Parts 210–211), ISO 13485 certification, Annex 1 compliance, and USP Chapter <797> and <800> compliance.
Core Federal & Commercial Capabilities:
Sterile Injectable Fill-Finish & Compounding: Large-volume sterile injectable fill-finish, Annex 1-compliant sterile fill-finish syringes, sterile injectable compounding, FDA-shortlisted drugs, and bacteriostatic water for injection (BWFI) in multi-dose vials.
Peptide API & Large-Scale Biologics: Solid-phase peptide synthesis (SPPS) for GLP-1 agonists (including tirzepatide and semaglutide analogs), large-scale recombinant protein production, and biosimilar drug manufacturing/compounding for insulin analogs (Icodec, Degludec, Glargine, Detemir, Aspart) and GLP-1/GIP dual agonists.
Drug Delivery Device OEM & Autoinjector Assembly: Ranked as the No. 5 leading insulin self-injection device OEM and 3 mL cartridge insulin delivery pen manufacturer with USFDA 506(e) registration. We provide 21 CFR 4 combination product contract manufacturing, ISO 13485 cleanroom device assembly services, custom pen injector device development, and high-volume autoinjector assembly for insulin pens, epinephrine auto-injectors, rheumatoid arthritis autoinjectors, prefilled syringes, and MDI/DPI inhalation therapeutics.
Partner with MayMag Biologics—your premier biologics drug delivery device contract manufacturer, recombinant insulin API supplier, and autoinjector CDMO manufacturing partner targeting FDA approval for interchangeable biosimilar insulin and commercial-scale insulin device manufacturing in the USA.

Comments
Post a Comment